Loading
Adding cisplatin to gemcitabine lengthened survival by more than three months in advanced bile duct and gallbladder cancer without extra serious toxicity, establishing the chemotherapy standard for the disease.
Phase 3 trial of 410 patients with locally advanced or metastatic cholangiocarcinoma, gallbladder or ampullary cancer randomised to cisplatin plus gemcitabine or gemcitabine alone for up to 24 weeks.
Median overall survival was 11.7 versus 8.1 months (hazard ratio 0.64) and progression-free survival 8.0 versus 5.0 months, with similar rates of grade 3 to 4 adverse events.
Gemcitabine-cisplatin is the backbone of first-line treatment for advanced biliary tract cancer, now combined with durvalumab or pembrolizumab.
Shares Extrahepatic cholangiocarcinoma (perihilar and distal), Gemcitabine, Cisplatin.
Shares Extrahepatic cholangiocarcinoma (perihilar and distal), Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials, Gemcitabine, Cisplatin.
Shares Extrahepatic cholangiocarcinoma (perihilar and distal), Gemcitabine, Cisplatin.
Shares Extrahepatic cholangiocarcinoma (perihilar and distal), Gemcitabine, Cisplatin.
Shares Extrahepatic cholangiocarcinoma (perihilar and distal), Gemcitabine, Cisplatin.
Shares Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials, Gemcitabine, Cisplatin.
Shares Extrahepatic cholangiocarcinoma (perihilar and distal), Gemcitabine, Cisplatin.
Shares ABC-02, Gemcitabine, Cisplatin.